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SUMMARY
The b1 integrins, known to promote cancer progression, are abundant in extracellular vesicles (EVs).
We investigated whether prostate cancer (PrCa) EVs affect anchorage-independent growth and
whether b1 integrins are required for this effect. Specifically using a cell-line-based genetic rescue
and an in vivo PrCa model, we show that gradient-purified small EVs (sEVs) from either cancer cells
or blood from tumor-bearing TRAMP (transgenic adenocarcinoma of the mouse prostate) mice pro-
mote anchorage-independent growth of PrCa cells. In contrast, sEVs from cultured PrCa cells
harboring a short hairpin RNA to b1, from wild-type mice or from TRAMP mice carrying a b1 condi-
tional ablation in the prostatic epithelium (b1pc/), do not. We find that sEVs, from cancer cells or
TRAMP blood, are functional and co-express b1 and sEV markers; in contrast, sEVs from b1pc//
TRAMP or wild-type mice lack b1 and sEV markers. Our results demonstrate that b1 integrins in
tumor-cell-derived sEVs are required for stimulation of anchorage-independent growth.
INTRODUCTION
Prostate cancer (PrCa) is one of the most frequently diagnosed cancers among men and remains a significant
clinical challenge (Siegel et al., 2018). Many factors contribute to disease progression and resistance to therapy,
including deregulated interactions between integrins and extracellular matrix (ECM) proteins (Fitzgerald et al.,
2008; Wang et al., 2011). Integrins are a class of heterodimeric transmembrane receptors consisting of a and b
subunits that modulate cell adhesion and migration in the tumor microenvironment by binding to specific
recognition peptide sequences (Lee et al., 2015; Plow et al., 2000). They signal through multiple downstream
effectors such as Src and focal adhesion kinase (FAK) to modulate important functions of both normal and can-
cer cells. In particular, b1 integrins are known to contribute to prostate tumor growth (Goel et al., 2010, 2013).
Our laboratory has previously shown in TRAMP (transgenic adenocarcinomaof themouse prostate)mice that b1
integrins contribute to resistance to radiation therapy by inhibiting c-jun NH2-terminal kinase (JNK) activity
(Goel et al., 2013; Sayeed et al., 2016). TRAMPmicewith a conditional b1 ablation in the prostate have increased
survival, decreased primary tumor burden, and decreased metastasis (Goel et al., 2013).
The b1 integrin subunit heterodimerizes withmany different a subunits. In epithelial cells, b1 is often pairedwith
a5 to function as the integrin receptor for fibronectin. The a5 subunit has been linked to cancer development
and progression. In particular, there are three different studies implicating the loss of certain microRNAs in
different cancers that are responsible for targeting a5 (Cimino et al., 2013; Gong et al., 2016; Yoo et al.,
2016). The a5b1 integrin has been implicated in increasing cancer cell migration, invasion, and resistance to
chemotherapy (Li et al., 2013; Miroshnikova et al., 2017; Paul et al., 2015; Zhu et al., 2017). However, there is
less known about the role of the a5b1 integrin in anchorage-independent cell growth.
PrCa cells are capable of transferring proteins, such as integrins, to other PrCa cells via extracellular vesicles
(EVs). EVs affect both cancer progression and response to cancer therapy (Minciacchi et al., 2015). There are
multiple subtypes of EVs, including microvesicles (50–2,000 nm), apoptotic bodies (50–5,000 nm) (Junker
et al., 2016; Kowal et al., 2016), and exosomes (exo), which range in size between 30 and 150 nm, and
are secreted by the fusion of the multivesicular endosomes with the plasma membrane of the cell (Co-
lombo et al., 2014). Exo can transfer crucial biological molecules between cells, affecting both normal
and pathological processes (Colombo et al., 2014; Tkach and Thery, 2016). Several molecules implicated
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in PrCa progression are enriched in exo from PrCa cells, including b1 integrins, insulin-like growth factor
receptor 1 (IGF-IR), and downstream signaling molecules such as c-Src and FAK (DeRita et al., 2017; Fedele
et al., 2015; Krishn et al., 2018, in press; Singh et al., 2016). In addition, exo-mediated transfer of integrins
between PrCa cells functionally affects recipient cancer cells (Fedele et al., 2015; Hamidi et al., 2016; Singh
et al., 2016). PrCa cell exo have also been shown to increase xenograft tumor size when injected intrave-
nously (Hosseini-Beheshti et al., 2016). Furthermore, large cancer-derived EVs called large oncosomes
(1–10 mm) were reported to transfer active AKT1 and increase fibroblast Myc activity after oncosome inter-
nalization (Minciacchi et al., 2017). In addition to pro-tumorigenic molecules, tumor suppressor proteins
such as maspin have also been detected in PrCa exo (Dean et al., 2017). Exo, oncosomes, and other can-
cer-derived EVs may be a source of biomarkers easily detectable in blood (Minciacchi et al., 2015, 2017) and
potentially linked to disease outcome and therapy response as observed for circulating tumor cells (You
et al., 2016). Owing to recent updates on EV research (Thery et al., 2018), this report uses the term small
EVs (sEVs) to describe the small (between 50 and 150 nm) EVs previously referred to as exo.
We demonstrate for the first time that tumor-derived b1 integrins are essential for supporting the ability to
stimulate anchorage-independent growth of EVs shed by PrCa cells and circulating in the plasma of tumor-
bearing mice. Although the significance of EVs in disease progression is recognized, there are no studies
showing that ‘‘tumor-cell-derived’’ EVs are physiologically active. We demonstrate in this study, using EVs
from in vitro and in vivo models, that tumor-cell-derived b1 integrins are required for EV-mediated stimu-
lation of anchorage-independent growth. Overall, this study sheds light on the role of EVs and b1 integrins
in the progression of PrCa.
RESULTS
b1 Integrins Are Required for Extracellular-Vesicle-Stimulated Anchorage-Independent
Growth of Prostate Cancer Cells
Our laboratory has previously demonstrated that integrins are expressed in PrCa-derived EVs (Fedele et al.,
2015; Krishn et al., 2018, in press; Lu et al., 2018; Singh et al., 2016) and that b1 integrins promote PrCa cell
growth and survival (Goel et al., 2009, 2010; Sayeed et al., 2012). To study b1 integrin function in PrCa EVs,
we optimized our purification protocol to improve the purity and reliability of our results. In this study, we
utilize small (less than 150 nm) EVs obtained from high-speed differential ultracentrifugation and EVs
further purified by flotation in a density gradient. Samples that have been further purified by flotation in
a density gradient have been designated small EVs (sEVs). All EVs and sEVs utilized are in the size and den-
sity range previously reported (Kowal et al., 2016). To validate the whole sEV isolation procedure, we
analyzed the levels of the sEV markers CD63, CD81, TSG101, and CD9 in each iodixanol gradient fraction
from a PC3-derived sEV sample and observed that their levels are the highest in the 1.112 g/mL density
fraction (Figures 1A and 1B, upper panels). The input material is shown in a lighter exposure (Figures 1A
and 1B, lower panels). Calnexin, an ER protein not found in EVs, is not present in these samples, confirming
the absence of any contaminants (Figure 1C). Our results confirm a previous study using an iodixanol den-
sity gradient in which the sEVs are present in the 1.115 g/mL fraction (Kowal et al., 2016). However, species
and biofluid of EV origin can affect the density, as we have found sEVs in the 1.14 g/mL fraction from plasma
samples (Krishn et al., 2018, in press). To functionally analyze sEVs from PrCa cells, we first demonstrated
that sEVs isolated from PC3 cells have the expected size range (Figure 2A) and are capable of stimulating
recipient cell anchorage-independent growth, as compared with vehicle treatment (Figures 2B and 2C).
Next, to elucidate the role of EV b1 integrins in stimulating anchorage-independent growth of PrCa cells, we
conducted in vitro and in vivo experiments. In the in vitro approach, we used PC3 cells with a knockdown of
the b1 integrin subunit (designated shb1 PC3 cells; Goel et al., 2010). As previously reported (Goel et al.,
2010), endogenous levels of b1 integrins in PC3 cells are required for the formation of large colonies in a soft
agarmatrix (Figure 3A).We then isolatedEVs from these cells usingdifferential ultracentrifugation.Nanoparticle
tracking analysis (NTA) reveals that there are no significant differences in the average particle size upon b1
downregulation (Figure 3B). Analysis of coloniesR25 mm in diameter, expressed as a percentage of the total
number of colonies, shows that the EVs from shb1 PC3 cells lose the ability to stimulate large colony growth
compared with their counterparts frommock PC3 cells (Figures 3C and 3D). As PC3 cells are a naturally aggres-
sive cell line and have an innate ability to form small colonies in standard media alone, we decided to evaluate
larger colonies with sizeR25 mm in diameter rather than the total colony number. The b1 integrin subunit has
many different binding partners in the cell, particularly a5 in epithelial cells, which has been previously associ-
ated with the progression of cancer (Cimino et al., 2013; Gong et al., 2016; Yoo et al., 2016). We therefore
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analyzed the levels of a5 in PC3 cells and EVs released by these cells upon b1 knockdown. Although the levels of
an EV marker, TSG101, are not modified upon b1 integrin downregulation (Figure 3F), a5 levels are reduced in
those EVs (Figure 3E), indicating that the a5 and b1 integrin subunits, as expected, are linked. We additionally
examined EV levels of FAK, a downstream effector of the a5b1 integrin, and find that it is also downregulated in
EVs upon short hairpin RNA (shRNA) targeting of b1 (Figure 3F). Furthermore, we observe that FAK is increased
in cells treated with EVs from b1-positive PC3 cells (Figure 3G). EVs from shb1 cells do not increase recipient cell
FAK levels. Owing to the decreased levels of FAK in shb1 EVs, it is likely that the EVs are transferring FAK to the
recipient cells (Figure 3G).
We then investigated whether the significant functional differences between EVs from shb1 and mock PC3
cells are due to differences in EV internalization. We treated DU145 PrCa cells with EVs labeled with PKH26
red dye and analyzed internalization by confocal microscopy. We observe that there is no difference in the
number of cells that internalized EVs from shb1 and mock PC3 cells (Figure S1). This indicates that EV-
derived b1 integrins play a functional role as signaling molecules rather than influencing EV internalization.
When cells were treated with only PKH26 dye without EVs, there was no evidence of red dye internalization
in recipient cells (unpublished data). Together, these results demonstrate the requirement of b1 integrins
for the ability of PrCa EVs to stimulate anchorage-independent growth.
Rescue of Functional b1 Integrins Restores the Stimulatory Function of Secreted EVs on
Anchorage-Independent Growth
To further demonstrate the importance of b1 integrin expression in PrCa cells for the anchorage-indepen-
dent function of EVs, we re-transfected shb1 PC3 cells with chicken b1 (Hayashi et al., 1990), which would
Figure 1. Validation of Extracellular Vesicle Isolation Procedure
(A) Upper panel: A representative immunoblotting is shown for CD63 and CD81 across 10 iodixanol density gradient
fractions. The two rightmost lanes represent the input material before iodixanol separation and a total cell lysate (TCL) of
the EV donor cells. Lower panel: a lighter exposure of the two rightmost lanes shown in the upper panel, also representing
the input material (‘‘Input’’ in upper panel or EVs in lower panel) and TCL of donor cells.
(B) Upper panel: Immunoblotting is shown for TSG101 and CD9 across 10 density gradient fractions. The two rightmost
lanes represent the input material before iodixanol separation and a total cell lysate (TCL) of the donor cells. Lower panel:
a lighter exposure of the two rightmost lanes shown in the upper panel, also representing the input material (noted as
‘‘Input’’ in upper panel and ‘‘EVs’’ in the lower panel) and TCL of EV donor cells. Results from (A) were obtained under non-
reducing conditions, and results from (B) were obtained under reducing conditions.
(C) Immunoblotting is shown for calnexin across 10 density gradient fractions. The rightmost lane represents the TCL from
PC3 cells. Results were obtained under non-reducing conditions.
iScience 14, 199–209, April 26, 2019 201
not be targeted by the shRNA against human b1. We first analyzed the total cell lysates (TCL) for chicken b1
expression after transfection and confirm specific expression of chicken b1 in transfected cells (Figure 4A).
To reach detectable levels of relevant proteins in TCL samples, we loaded nearly three times the amount of
protein (Figure 4A) as we did when analyzing proteins in EV samples (Figure 3E). Flow cytometric analysis of
those transfected cells also confirms the expression of chicken b1 on the cell surface (Figure 4B). Next, we
analyzed the EVs released by those cells. NTA shows that there are no significant differences between the
size and abundance of EVs from shb1 PC3 cells transfected with chicken b1 and those transfected with
empty vector (Figure 4C). We observe that the EVmarkers CD63, CD81, TSG101, and CD9 are also enriched
in the EVs compared with TCL (Figures 4D and 4E). The levels of total b1 are increased in EVs from shb1 PC3
cells transfected with chicken b1, along with the downstream signaling protein c-Src (Figure 4E).
We then treated PC3 cells with EVs from shb1 PC3 cells transfected with chicken b1 or empty vector and
analyzed their anchorage-independent growth. We clearly demonstrate that transfection of shb1 cells
with chicken b1 rescues the ability of EVs to stimulate large colony growth of recipient PC3 cells (Figure 4F).
Once again, coloniesR25 mm were counted 2 weeks after seeding in soft agar and expressed as either an
absolute number or a percentage of total number of colonies (Figure 4F, left and right panels). EVs from
shb1 PC3 cells transfected with an empty vector caused significantly less colony growth than EVs from
the shb1 PC3 cells that were transfected with chicken b1 (Figures 4F and 4G).
Prostate-Specific Ablation of b1 Integrins in Mice Alters the Protein Content, Physical
Properties, and Function of Circulating EVs
The in vitro results prompted us to analyze circulating plasma sEVs from the TRAMP mouse model. After
sEV isolation from the plasma of TRAMP mice (n = 6), we demonstrate that the sEV markers CD63 and
CD9 are present in the expected sEV density fraction (1.14 g/mL, based on previous study from our labo-
ratory using human plasma; Krishn et al., 2018, in press) (Figure 5A, right panel)]. We had previously used
sucrose density gradient separation to demonstrate enriched levels of b1 integrins and c-Src in sEVs from
PrCa cells. Here we confirm that both b1 and c-Src are present predominantly in the same iodixanol density
fraction (1.14 g/mL) of TRAMP sEVs as markers CD63 and CD9 (DeRita et al., 2017) (Figure 5A, right panel).
Calnexin is absent from these samples (unpublished data). Conditional ablation of b1 from the prostatic
Figure 2. sEVs from PrCa Cells Stimulate Recipient Cell Anchorage-Independent Growth
(A) NTA of the 1.112 g/mL fraction containing PC3-derived sEVs isolated using an iodixanol density gradient. The
experiment was repeated three times.
(B) Quantification of anchorage-independent growth of PC3 cells after treatment with sEVs (1.112 g/mL fraction) from PC3
cells. Data are represented as mean G SEM. *p < 0.000067 (Student’s t test).
(C) Representative images of the data quantified in (B) are shown.
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epithelium in TRAMPmice (b1pc//TRAMP) alters the protein composition and density distribution of sEVs
from the blood of these mice (n = 8). The sEV marker CD9 is undetectable in the 1.14 g/mL density fraction.
b1 and the downstream signaling protein c-Src, which we have previously shown to be enriched in PrCa
EVs (DeRita et al., 2017), are also absent (Figure 5A, left panel). We performed analysis on non-tumor-
bearing wild-type mice (n = 6) as well and observe that there is no detectable b1, CD63, or CD9 in either
the 1.14 g/mL fraction or any of the other nine density gradient fractions (Figure 5A, middle panel). In addi-
tion, NTA of the 1.14 g/mL fraction shows that the amount of sEVs is approximately two times higher in
TRAMP mice versus b1pc//TRAMP mice, whereas the difference between wild-type and TRAMP was
less pronounced (Figure 5B and Table 1). However, the tumor masses at the age of 20 weeks are statistically
similar between TRAMP and b1pc//TRAMP mice (Table 1); this is consistent with our previous findings
that b1 plays a role in PrCa progression beyond 20 weeks in TRAMP mice (Goel et al., 2013). The reduction
in the number of sEVs in the 1.14 g/mL fraction between TRAMP and b1pc//TRAMP mice is not due to a
reduction in tumor size, but rather due to the fact that b1 integrins in the tumor epithelium may have a role
specifically in sEV formation and secretion. Altogether, these data suggest that the b1-positive PrCa tumor
epithelial cells are the predominant source of circulating b1 in sEVs and that b1 integrins in the prostatic
epithelium contribute to sEV processing into circulation.
Stimulation of Anchorage-Independent Growth by Tumor-Derived Circulating sEVs
Is Dependent on b1 Integrins
To see if the effects of cancer-cell-derived EVs are tumor specific and transferrable to an in vivo setting,
we next analyzed if there was a difference in function between b1-positive sEVs from TRAMP mice and
Figure 3. b1 Integrins from PrCa Cells Are Required for EV-Mediated Stimulation of Anchorage-Independent
Growth
(A) Quantification of anchorage-independent growth of shb1 or mock PC3 cells with no other treatments. The total
number of colonies were counted per field (325 3 250 mm) after 4 weeks in soft agar. p < 0.0000013.
(B) NTA profiles of the EV population isolated from PC3 cells transfected either with shRNA to b1 (shb1) or an empty vector
(mock). Three technical replicates were performed on each sample. The area under the curve represents all detected
particles in the sample and an average of three independent readings.
(C) Quantification of anchorage-independent growth of PC3 cells after treatment with EVs from either shb1 or mock PC3
cells. Data are represented as mean G SEM. *p < 0.045, **p < 0.0045 (Student’s t test).
(D) Representative images of the data quantified in (C) are shown. Two technical and biological replicates were
performed.
(E) Immunoblotting of both EVs and total cell lysates (TCL) from shb1 andmock PC3 cells for b1, TSG101, and calnexin (left
panel); and for a5 (right panel); 15 mg protein was loaded per lane, and results were obtained in reducing conditions.
(F) Immunoblotting of EVs from shb1 or mock PC3 cells for FAK and TSG101; 15 mg protein was loaded per lane.
(G) Immunoblotting for FAK and ERK of TCL from PC3 cells incubated with EVs from shb1 PC3 cells, mock PC3 cells, or
PBS; 40 mg protein was loaded per lane.
See also Figure S1.
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b1-negative sEVs from wild-type mice. PC3 cells were treated with equal numbers of sEVs from the plasma
of either TRAMP or wild-typemice and then analyzed for anchorage-independent growth. It is clear that the
b1-positive sEVs from TRAMP mice are able to stimulate anchorage-independent growth, whereas b1-
negative sEVs from wild-type (non-tumor-bearing) mice do not (Figures 6A and 6B).
Given that the functional studies were performed by treating recipient cells with equal numbers of particles
from TRAMP and wild-type sEV samples, we wanted to biochemically examine gradient-purified sEV con-
tent in the same manner. Immunoblotting on equal numbers of vesicles was performed (Figure 6C). We
observe, similar to when the samples were loaded based on volume in Figure 5A, that sEVs from wild-
type mice do not exhibit the sEV marker CD63, b1, or c-Src. They also lack a5. This shows that
even when examining equal numbers of vesicles, there is a dramatic difference in sEV cargo between
Figure 4. Rescue of b1 Expression Restores the Stimulatory Function of Secreted Extracellular Vesicles on
Anchorage-Independent Growth
(A) Immunoblotting for chicken b1, total b1, and a5 of TCL from shb1 PC3 cells transfected with either full-length chicken
b1 (chick b1) or empty vector (mock) alone. Results for chicken-specific b1 (chick b1) were obtained under non-reducing
conditions, whereas the results for total b1 (b1 total) were obtained under reducing conditions. AKT is used as a loading
control; 50 mg protein was loaded per lane.
(B) Flow cytometric analysis of shb1 cells transfected with either chicken b1 or empty vector using an Ab specific to chicken
b1 integrin.
(C) NTA of EVs derived from shb1 cells transfected with either chicken b1 or vector. Three technical replicates were
performed on each sample.
(D) Immunoblotting for calnexin and the EV markers CD63 and CD81.
(E) Immunoblotting for a5, total b1, c-Src, TSG101, and CD9 of EVs and TCL from shb1 cells transfected with either chicken
b1 or empty vector. For data in (D and E), 15 mg protein per lane was loaded.
(F) Left panel: quantification of anchorage-independent growth of PC3 cells after treatment with EVs derived from shb1
cells transfected with either chicken b1 or empty vector. The number of coloniesR25 mm per field (325 3 250 mm) was
quantified and reported as an absolute number after 2 weeks in soft agar. *p < 0.002. Right panel: quantification of
anchorage-independent growth of PC3 cells after treatment with EVs derived from shb1 cells transfected with either
chicken b1 or mock vector. The number of coloniesR25 mm per field (325 3 250 mm) was quantified and reported as
percentage of the total after 2 weeks in soft agar. Data are represented as mean G SEM. *p < 0.002 (Student’s t test).
(G) Representative images of data quantified in (F) are shown.
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wild-type and TRAMP mice. Transmission electron microscopy displays standard size and morphology of
sEVs isolated from the wild-type mice (Figure 6D) despite not exhibiting the standard protein signature
seen in TRAMP mice sEVs (Figure 6C) and PrCa cell-line-derived sEVs (Figure 1).
To validate the function of EV-derived a5b1 observed ex vivo, we first pre-treated EVs from TRAMP mice
with ATN-161, an inhibitory peptide to the a5b1 integrin, before incubating themwith PC3 cells and assess-
ing their anchorage-independent growth. The concentration of ATN-161 (100 mg/mL) has been previously
validated by another group while studying mouse a5b1 function in vitro (Sundaram et al., 2017). Colonies
whose sizes were R25 mm were quantified and expressed as a percent of the total number of colonies.
ATN-161 pre-treatment of TRAMP mouse-derived EVs significantly reduces the colony size of EV recipient
cells compared with RGE-containing control peptide and vehicle pre-treatment (Figures 6E and 6F). These
results show that the a5b1 integrin plays a crucial role in EV-mediated stimulation of anchorage-indepen-
dent growth of PrCa cells. The effects observed with ATN-161 on the EVs is not due to any residual free-
floating inhibitor binding directly to the cells because a separate experiment shows that ATN-161 treat-
ment of the cells in the absence of sEVs does not significantly alter their anchorage-independent growth
(unpublished data).
As the circulating b1 integrin-containing EVs can originate from a plethora of organs and tissues, we next
sought to analyze the role of prostate-derived EV b1 integrins in anchorage-independent growth of cancer
cells. We utilized tumor-bearing b1pc//TRAMP mice. After isolating plasma-derived EVs, we evaluated
EV abundance and size distribution by NTA. The average EV size from b1pc//TRAMP mice was
Figure 5. Prostate-Specific Ablation of b1 Integrins Alters the Protein Content and Physical Properties of
Circulating Extracellular Vesicles
(A) Immunoblotting is shown for b1, c-Src, CD63, and CD9 across 10 iodixanol density gradient fractions obtained from
b1pc//TRAMP (left panel), wild-type (middle panel), and TRAMP (right panel) mouse EVs. For adequate input material,
EV samples from three mice were pooled before gradient separation. The rightmost lane on the middle and right panels
represents a positive control EV sample from a wild-type (middle panel) or TRAMP (right panel) mouse, i.e., the pellet
obtained after initial EV precipitation.
(B) Graphical representation of NTA of the 1.14 g/mL sEV fraction of the iodixanol density gradient from b1pc//TRAMP
(left panel), wild-type (middle panel), or TRAMP (right panel) mice. The experiment was repeated twice, and results were
obtained from pooled samples from three mice for each condition. A total of six TRAMP, eight b1pc//TRAMP, and six
wild-type mice were analyzed.
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121.9 nm and the average EV concentration was 4.7 3 1010 EVs/mL of plasma (Figure 6G). The average size
of TRAMP EVs was similar (118.0 nm), whereas the concentration (10.5 3 1010 EVs/mL of plasma) was twice
the amount of b1pc//TRAMP EVs. This is to be expected given our previous results examining gradient-
purified sEVs (Table 1). To determine if prostate-specific b1 is affecting EV function, we analyzed PC3
anchorage-independent growth in response to prostate-derived TRAMP EVs. EVs from b1pc//TRAMP
mice do not stimulate anchorage-independent growth of PC3 cells, indicating the importance of b1 expres-
sion in the prostate tumor epithelium to the oncogenic ability of secreted EVs (Figure 6H).
DISCUSSION
b1 integrins are expressed in many different cell types and contribute to prostate tumor growth. Our study
is the first to demonstrate that b1 integrins in EVs, including sEVs, specifically from prostate tumor epithelial
cells, or PrCa cultured cells, mediate the stimulatory function of secreted EVs on anchorage-independent
growth. Through the use of a genetic mouse model and cell-line-based genetic rescue, we demonstrate
that b1 integrins are required for the stimulatory effects of EVs derived from cancer cells on anchorage-in-
dependent growth.
b1 integrins may affect the anchorage-independent functions of EVs on recipient cells in multiple ways. b1
integrins are heavily trafficked between the cell surface and endosomal pathway (De Franceschi et al., 2015;
Huet-Calderwood et al., 2017) and are known to signal through endosomes (Alanko et al., 2015); thus they
are likely to influence the biology of secreted EVs. Another possible role for b1 in EV functions is that they
may influence the composition of EVs secreted from cancer cells as shown in a previous study from our lab-
oratory on other integrins (Lu et al., 2018). Finally, as it is known that a single cell type can produce many
different subsets of EVs, it is possible that b1 integrins are contributing to the biogenesis of, and are carried
in, a specific subset of EVs that exhibit tumorigenic effects on recipient cells. Our results indicate that b1
may be playing its role in stimulating anchorage-independent growth at the cell surface, but does not affect
the ability of EVs to be internalized by recipient cells.
We have established a requirement for b1 in circulating EVs to stimulate in vitro anchorage-independent
growth, which suggests that these EVs are able to potentially modulate both primary and metastatic tumor
growth. Furthermore, there is evidence of integrins from cancer-derived EVs altering the function of other
non-epithelial, non-cancerous cell types. For example, exo from myeloid leukemia cells have been shown
to stimulate angiogenic behavior of recipient endothelial cells (Mineo et al., 2012). Another study has
shown that pancreatic cancer-derived exo contribute to pre-metastatic niche formation in the liver
(Costa-Silva et al., 2015). Furthermore, we have previously demonstrated the transfer of b6-positive EVs
to monocytes, causing their M2 polarization (Lu et al., 2018).
b1 integrin-mediated signaling occurs through a complex network of proteins, including JNK, Src, IGF-IR
(Goel et al., 2013; Sayeed et al., 2013, 2016; Varkaris et al., 2014), and FAK, a non-receptor tyrosine kinase
that, with Src, coordinates cell adhesion and cytoskeletal dynamics and regulates cancer cell migration
and invasion (Varkaris et al., 2014). Our previous studies have shown that FAK, Src, and IGF-IR are de-
tected in PrCa EVs and thus may be involved in EV-mediated tumorigenic cell growth. We have previ-
ously demonstrated a functional interdependence between the a5b1 integrin and IGF-IR in PrCa cells
and that this interaction influences androgen receptor activity and cancer cell growth (Sayeed et al.,
2012). IGF-IR specifically stabilizes the a5b1 integrin by preventing proteasomal degradation but has
no effect on the a2, a4, a6, and a7 subunits (Sayeed et al., 2013). Given the importance of integrin
Mouse Genotype Average Tumor Mass
(Age 20 Weeks)
Average Plasma sEV
Concentration (1010 sEV per mL Plasma)
TRAMP 132.2 mg 3.1
b1pc//TRAMP 207.5 mg 1.7
Wild-type No tumor present 2.3
Table 1. Analysis of EV Abundance from TRAMP, b1pc//TRAMP, and Wild-type Mice
The average values of the sEV concentration (particles from the 1.14 g/mL iodixanol density gradient fraction) are reported.
For average tumor mass between TRAMP and b1pc//TRAMP mice, p > 0.05 (non-significant). TRAMP: n = 6; b1pc//
TRAMP: n = 8; wild-type: n = 6.
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function and integrin-IGF-IR cross talk in cancer cell growth (Sayeed et al., 2012, 2013, 2016), and IGF-IR
enrichment in PrCa EVs (DeRita et al., 2017), IGF-IR may support a5b1 stability and promote EV functions.
FAK is also associated with b1 signaling and cancer cell survival in the absence of ECM attachment
(Alanko et al., 2015). As we see that EV FAK levels correlate with b1 and that recipient cells have
increased FAK upon transfer of b1 and FAK-positive EVs, it is possible that FAK is also a driver of EV-
mediated stimulation of cancer cell anchorage-independent growth.
Our findings implicate that b1 integrins in the prostate tumor epithelium may be involved in the formation
and secretion of EVs. This was evidenced by the fact that the total number of circulating EVs was twice as
high in the TRAMP mice compared with the b1pc//TRAMP mice, which at 20 weeks show comparable tu-
mor sizes (Table 1). We have also demonstrated that the prostate tumor epithelial cells are responsible for
nearly all the circulating b1-positive EVs that express canonical markers such as CD9 and CD63. Overall, this
study demonstrates that circulating EV b1 integrins shed by prostate tumors are activators of cancer cell
growth, thus opening new perspectives in translational medicine and cancer treatment.
Figure 6. Stimulation of Anchorage-Independent Growth by Tumor-Derived Circulating EVs Is Dependent on b1
Integrins
(A) Quantification of anchorage-independent growth of PC3 cells after treatment with sEVs from TRAMP and wild-type
mice. *p < 0.0004.
(B) Representative images of the data quantified in (A) are shown. The experiment was repeated three times. All mice were
aged 20 weeks at the time of sacrifice, blood collection, and EV analysis.
(C) Immunoblotting of gradient-purified sEVs of the indicated densities for b1, a5, c-Src, and CD63. For b1, a5, and c-Src
7.5 3 108 sEVs were loaded per lane and analyzed under reducing conditions. For CD63, 7.5 3 107 sEVs were loaded per
lane and analyzed under non-reducing conditions.
(D) Transmission electronmicroscopy of mouse-derived, gradient-purified sEVs obtained from a pool of either three wild-
type (upper panel) or three TRAMP (lower panel) mice. Upper panel, 26K magnification; lower panel, 32K magnification;
scale bar, 50 nm.
(E) Quantification of anchorage-independent growth of PC3 cells incubated with TRAMPmouse plasma-derived EVs, pre-
treated with ATN-161, an a5b1 inhibitory peptide; control peptide GRGESP (RGE); or PBS vehicle. Data are represented
as meanG SEM. **p < 0.0000072, *p < 0.0015 (Student’s t test). Two technical and biological replicates were performed.
(F) Representative images of the data quantified in (E).
(G) NTA of EVs from b1pc//TRAMP mice.
(H) Quantification of anchorage-independent growth of PC3 cells after treatment with b1pc//TRAMP or TRAMP EVs.
*p < 1.4 3 106. Two technical and biological replicates were performed.
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Limitations of the Study
This study performed using a mouse model needs to be translated in human subjects. Furthermore, at this
time, although the results may be informative for early-stage cancer diagnosis, they may not provide
insightful information on advanced disease.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.03.022.
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TRANSPARENT METHODS  
 
Cell lines and transfectants 
PC3 PrCa cells (from a male patient) were maintained as described previously (DeRita et al., 
2017).  Stably transfected PC3 cells with shRNA to β1 (“shβ1”) and mock vector-transfected 
(“mock”) were generated as described previously (Goel et al., 2010).  PC3 shβ1 and mock cells 
were further transfected with pECE vector (used as negative control) and pECE-chicken-β1 (full 
length chicken β1) (Hayashi et al., 1990) using the Lipofectamine 2000 reagent (Thermo Fisher 
Scientific) at a ratio of 3  µL Lipofectamine/µg of DNA.  After 48 hours, the transiently 
transfected cells were processed for cell surface expression of chicken β1 using FACS analysis 
with the CSAT Ab specific to chicken β1 (10 µg/mL) or mouse IgG (negative control).  Samples 
were then incubated with an Alexa Fluor 488 goat anti-mouse secondary Ab (20 µg/mL), washed 
in PBS (3X) and the data were analyzed using the BD Celesta flow cytometer (BD Biosciences). 
 
Animals  
All male TRAMP, β1pc-/- /TRAMP and Wild-Type mice were generated as described earlier (Goel 
et al., 2013).  For TRAMP: n = 6; for Wild-Type: n = 6; for β1pc-/- /TRAMP: n = 8. No female 
mice were analyzed in this study. Care of animals was in compliance with standards established 
by the office of laboratory animal welfare, Department of Health and Human Services at NIH.  
Experimental protocols were approved by the Institutional Animal Care and Use Committee.  
 
Immunoblotting    
Immunoblotting of EV and EV lysates were performed as reported earlier (Sayeed et al., 2013; 
Trerotola et al., 2015).  In brief, we separated sample lysates on sodium dodecyl sulfate PAGE, 
and transferred to 0.45 µm polyvinylidene difluoride (PVDF) membranes. Membranes were then 
blocked with 5% milk and incubated with primary and secondary antibodies.     
 
Antibodies (Ab) 
Blocked membranes were probed with either rabbit polyclonal antibodies (pAbs) to human and 
mouse calnexin (sc713), human and mouse c-Src (sc18), human and mouse FAK (sc558), human 
and mouse AKT (sc8312), and human and mouse ERK1/2 (sc292838) from Santa Cruz, human 
and mouse α5 integrin (#4705) from Cell Signaling, rabbit monoclonal Abs (mAbs) to human and 
mouse TSG101 (ab125011) and mouse CD63 (ab193349) from Abcam, mouse mAbs to human 
CD81 (ab23505) and human CD63 (ab8219) from Abcam, human and mouse β1 integrin (C-18) 
from BD Pharmingen, chicken β1 integrin (CSAT) from DSHB of University of Iowa, and 
human CD9 (sc13118) from Santa Cruz, or a rat mAb to mouse CD9 (Santa Cruz sc18869).  
 
EV isolation 
EV isolation from cells in culture was performed using differential ultracentrifugation (100,000 x 
g), as described previously (DeRita et al., 2017; Fedele et al., 2015).  At 20 weeks of age, when 
palpable tumors have formed, intracardiac blood withdrawal from animal subjects and EV 
isolation were performed as previously described via PEG precipitation (ExoquickTM) (DeRita et 
al., 2017), followed by density gradient separation (see next paragraph). 
 
Density gradient isolation of small (sEVs)  
The resulting pellet from 500 µL of mouse plasma or 10 confluent 150 mm dishes of PC3 cells 
after either ultracentrifugation or PEG precipitation was resuspended in 100 µl PBS and then 
subjected to density gradient separation to isolate the sEVs from any non-vesicular material co-
precipitated during ultracentrifugation or PEG precipitation.  We used a modified version of the 
protocol described by Kowal et al (Kowal et al., 2016).  In short, 100 (or up to 300 µl if pooling 
EV samples from the same condition) of the EV suspension was mixed with 500-700 µl tris-
sucrose buffer (total 800 µl) (Kowal et al., 2016).  This mixture was then combined with 800 µl 
60% stock Iodixanol solution (Sigma) to make a 30% solution.  On top of this 700 µl of 20%, 
then 700 µl 10% iodixanol solutions were carefully layered (Iodixanol solutions were diluted with 
the tris-sucrose buffer) to a total volume of 3 mL.  The discontinuous gradient was then 
ultracentrifuged at 350,000 x g for 1 hour at 4 °C using the sw55Ti rotor (Beckman).  Then, ten 
260 µl fractions were taken sequentially from the top.  The density of each fraction was measured 
(DeRita et al., 2017; Singh et al., 2016).  To remove sEVs from iodixanol, each fraction was then 
subjected to 100,000 x g spin, resuspension in PBS, another 100,000 x g spin, and final 
resuspension in 75 µl PBS.  These samples were stored at -80 °C.   
 
Nanoparticle Tracking Analysis (NTA) of EVs  
EVs were resuspended in PBS and diluted 1:1000.  Small EV (sEV) fractions obtained from the 
iodixanol gradient were diluted 1:300 for in vitro derived PC3 EVs and 1:30 for mouse plasma-
derived sEVs after density gradient separation.  The samples were analyzed as previously 
described using the NTA 3.1 Build 3.1.46 software and the NS 300 instrument (Malvern 
Instruments, MA)  (DeRita et al., 2017). 
 
Transmission Electron Microscopy  
A 3 µl volume of each sample was applied to a holy carbon grid that was glow discharged for 30 
seconds. A solution of 2% uranyl acetate was freshly made in deionized water. Each sample was 
then stained twice with 3 µl of 2% uranyl acetate.  Excess stain and sample were blotted away 
with a Whatman filter and the grid was let to dry until imaged.  TEM micrographs were collected 
using Tecnai TF20 FEG TEM microscope and the images were recorded on Falcon III direct 
electron detector. 
 
Anchorage-independent growth assay 
PC3 cells after EV treatment were measured for anchorage-independent growth.  PC3 cells were 
plated in 6-well plates to 75% confluency and serum-starved for 5 hours.  After starvation, cells 
were treated with either PEG-precipitated EVs from mouse plasma (100 µg/mL, with a range of 
9.6 x 107 - 2.6 x 1010 EVs/mL), gradient-purified EVs from mouse plasma (7.5 X 107 sEVs/mL), 
ultracentrifugation-isolated sEVs from shβ1 or mock PC3 cells (9 X 1010 EVs/mL), gradient-
purified EVs from PC3 cells (21 µg/mL, with a range of 12.6 x 108 – 6.3 x 109 EVs/mL), or 
vehicle (PBS).  For β1 integrin inhibition, the EVs were pre-treated with 100 µg/mL ATN-161 
(AcPHSCNNH2) (Tocris) or control GRGESP peptide (Gibco) at 4 °C for 45 minutes prior to cell 
treatment.  EV concentration was always matched between samples for each experiment.  EV 
treatment was overnight for 16-18 hours in serum-free media.  The next day, new 6-well plates 
were then coated with 0.8% agarose to create a basement layer.  Treated cells were trypsinized 
and 5,000 cells from each well were resuspended in 2 ml of 2X RPMI containing 10% FBS. The 
cell suspension was then mixed with 0.2 ml of 3% agarose; 2 ml of this mixture was layered 
gently on top of the basement layer to seed cells in a final concentration of 0.3% soft agar matrix.  
After solidification, 0.5 ml full media was added to prevent drying.  Each condition was 
performed in duplicate.  After two weeks (or four weeks for results in Figure 3A), all colonies 
were counted and classified by size via the NIS-Elements-F software and Nikon Eclipse TS100 
microscope.  Ten to twelve random optical fields were counted per experimental condition at 40x 
magnification.  The number of colonies ≥ 25 µm out of the total number of colonies per field (325 
x 250 µm) was quantified and reported as a percentage after 2 weeks in soft agar.   
 
Confocal microscopy and EV transfer 
DU145 prostate cancer cells grown on fibronectin coated (10 µg/ml) glass coverslips were serum-
starved for 24 h followed by incubation with PKH26 red dye (Mini26, Sigma-Aldrich) labeled 
EVs (20 µg/ml, ~1011 vesicles) from PC3-Mock and PC3-shβ1cells or PKH26 red dye in PBS 
alone for 24 h.  The cells on coverslips were then washed with PBS (2 washes), fixed with 4% 
PFA for 15 min at room temperature, washed with PBS (3 washes), quenched with 50 mM 
NH4Cl for 15 min, washed with PBS (2 washes), permeabilized with 0.1% Triton X-100 for 10 
min, washed with PBS (3 washes), blocked with 5% BSA, stained with FITC-conjugated 
phalloidin (2 µg/ml, Sigma-Aldrich, Cat. # P-5282) for 1 h at room temperature, washed with 
PBS (3 washes), and mounted on glass slides using ProLong™ diamond antifade mountant with 
DAPI (Invitrogen).  The cells on coverslips were imaged by Nikon A1R confocal microscope. A 
Z-stack image analysis was done by NIS Elements Viewer software (version 4.11.0) to evaluate 
PKH26 red dye labeled EV internalization into DU145 cells. 
 
Statistical Analysis 
Unless otherwise indicated, data in the figures are presented as mean ± SEM, and significant 
differences between experimental groups were determined using the 2-tailed Student’s t test.  A 
two-sided P value of less than 0.05 was considered statistically significant. 
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Figure S1: Down-regulation of β1 does not affect extracellular vesicle internalization, 
related to Figure 3. (A) DU145 cells were incubated with PKH26 - labeled EVs from either shβ1 
or mock PC3 cells for 24 hours and confocal microscopy was carried out to evaluate EV 
internalization.  DAPI was used to detect nuclei (blue), FITC-labelled Phalloidin was used to 
label actin (green), and PKH26 Red was used to label the EVs (red).  Z-stack analysis was used to 
determine the presence of EVs inside the cells versus the cell surface. (B) The percent of total 
cells showing internalized EVs was quantified and reported.   
  
